UroGen Pharma Ltd. (URGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q1 '17: 19K Q2 '17: 0 Q3 '17: 7.8M Q4 '17: 327K Q1 '18: 481K Q2 '18: 364K Q3 '18: 283K Q4 '18: 0 Q1 '19: 0 Q2 '19: 18K Q3 '19: 0 Q4 '19: 0 Q2 '20: 372K Q3 '20: 3.5M Q4 '20: 8M Q1 '21: 7.5M Q2 '21: 13M Q3 '21: 11.4M Q4 '21: 16.2M Q1 '22: 13.6M Q2 '22: 16.6M Q3 '22: 16.1M Q4 '22: 18.1M Q1 '23: 17.2M Q2 '23: 21.1M Q3 '23: 20.9M Q4 '23: 23.5M Q1 '24: 18.8M Q2 '24: 21.8M Q3 '24: 25.2M Q4 '24: 24.6M Q1 '25: 20.3M Q2 '25: 24.2M Q3 '25: 27.5M Q4 '25: 37.8M Q1 '26: 51M Q2 '26: 72.5M Q2 '17 Q3 '18 Q4 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-25M 0 25M 50M 75M Q1 '17: 1K Q2 '17: 0 Q3 '17: 7.5M Q4 '17: 40K Q1 '18: 51K Q2 '18: 46K Q3 '18: -772K Q4 '18: 0 Q1 '19: 0 Q2 '19: 18K Q3 '19: 0 Q4 '19: 0 Q2 '20: 324K Q3 '20: 3.2M Q4 '20: 7.3M Q1 '21: 6.6M Q2 '21: 11.6M Q3 '21: 10.1M Q4 '21: 14.6M Q1 '22: 12M Q2 '22: 14.8M Q3 '22: 14.1M Q4 '22: 15.8M Q1 '23: 14.9M Q2 '23: 18.7M Q3 '23: 18.5M Q4 '23: 21.2M Q1 '24: 17.1M Q2 '24: 19.6M Q3 '24: 22.8M Q4 '24: 22.1M Q1 '25: 17.9M Q2 '25: 20.7M Q3 '25: 24.2M Q4 '25: 34.5M Q1 '26: 46.8M Q2 '26: 65.9M Q2 '17 Q3 '18 Q4 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '17: -3.5M Q2 '17: -6M Q3 '17: -303K Q4 '17: -10.2M Q1 '18: -13.6M Q2 '18: -18.4M Q3 '18: -21.1M Q4 '18: -24M Q1 '19: -22.4M Q2 '19: -23.8M Q3 '19: -23.5M Q4 '19: -39.8M Q1 '20: -38.6M Q2 '20: -31.8M Q3 '20: -29.1M Q4 '20: -27.3M Q1 '21: -26.1M Q2 '21: -22.8M Q3 '21: -23.4M Q4 '21: -19.9M Q1 '22: -22M Q2 '22: -18.7M Q3 '22: -18.1M Q4 '22: -20.3M Q1 '23: -22M Q2 '23: -15.4M Q3 '23: -13.5M Q4 '23: -14.6M Q1 '24: -25.7M Q2 '24: -25.8M Q3 '24: -17.5M Q4 '24: -27.7M Q1 '25: -36.9M Q2 '25: -41.4M Q3 '25: -27.4M Q4 '25: -19.1M Q1 '26: -20.3M Q2 '26: 111K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '17: -3.4M Q2 '17: -6.2M Q3 '17: -298K Q4 '17: -10.1M Q1 '18: -13.4M Q2 '18: -18M Q3 '18: -20.5M Q4 '18: -23.7M Q1 '19: -21.4M Q2 '19: -22.5M Q3 '19: -22.3M Q4 '19: -39M Q1 '20: -37.8M Q2 '20: -31.3M Q3 '20: -28.8M Q4 '20: -30.5M Q1 '21: -25.9M Q2 '21: -26.2M Q3 '21: -30.2M Q4 '21: -28.5M Q1 '22: -28.4M Q2 '22: -26.7M Q3 '22: -25.8M Q4 '22: -28.9M Q1 '23: -30.2M Q2 '23: -24.1M Q3 '23: -21.9M Q4 '23: -26M Q1 '24: -32.3M Q2 '24: -33.4M Q3 '24: -23.7M Q4 '24: -37.5M Q1 '25: -43.8M Q2 '25: -49.9M Q3 '25: -33.3M Q4 '25: -26.4M Q1 '26: -23.6M Q2 '26: -14.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '17: 18K Q2 '17: 0 Q3 '17: 295K Q4 '17: 287K Q1 '18: 430K Q2 '18: 318K Q3 '18: 1.1M Q4 '18: 0 Q2 '20: 48K Q3 '20: 309K Q4 '20: 652K Q1 '21: 897K Q2 '21: 1.4M Q3 '21: 1.2M Q4 '21: 1.6M Q1 '22: 1.5M Q2 '22: 1.8M Q3 '22: 2M Q4 '22: 2.3M Q1 '23: 2.3M Q2 '23: 2.4M Q3 '23: 2.4M Q4 '23: 2.3M Q1 '24: 1.7M Q2 '24: 2.2M Q3 '24: 2.5M Q4 '24: 2.5M Q1 '25: 2.3M Q2 '25: 3.5M Q3 '25: 3.3M Q4 '25: 3.3M Q1 '26: 4.1M Q2 '26: 6.6M Q3 '17 Q4 '18 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '17: -2.7M Q2 '17: -3.5M Q3 '17: 2.6M Q4 '17: -6M Q1 '18: -9.6M Q2 '18: -8.1M Q3 '18: -9.3M Q4 '18: -10.3M Q1 '19: -17.9M Q2 '19: -14.6M Q3 '19: -12.5M Q4 '19: -26M Q1 '20: -35.6M Q2 '20: -23.9M Q3 '20: -25.1M Q4 '20: -21.2M Q1 '21: -27.4M Q2 '21: -18.9M Q3 '21: -18.5M Q4 '21: -20.1M Q1 '22: -24M Q2 '22: -24.2M Q3 '22: -17.6M Q4 '22: -21.8M Q1 '23: -25.8M Q2 '23: -20.3M Q3 '23: -17.3M Q4 '23: -13M Q1 '24: -31.7M Q2 '24: -23.7M Q3 '24: -27.7M Q4 '24: -13.6M Q1 '25: -42M Q2 '25: -39.8M Q3 '25: -42.3M Q4 '25: -38.3M Q1 '26: -45.3M Q2 '26: -33M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '17: -2.8M Q2 '17: -3.5M Q3 '17: 2.6M Q4 '17: -6.1M Q1 '18: -9.7M Q2 '18: -8.3M Q3 '18: -9.6M Q4 '18: -10.3M Q1 '19: -18M Q2 '19: -14.6M Q3 '19: -12.6M Q4 '19: -26.2M Q1 '20: -35.7M Q2 '20: -24.2M Q3 '20: -25.7M Q4 '20: -21.4M Q1 '21: -27.7M Q2 '21: -19M Q3 '21: -18.7M Q4 '21: -20.3M Q1 '22: -24M Q2 '22: -24.3M Q3 '22: -17.8M Q4 '22: -21.8M Q1 '23: -25.8M Q2 '23: -20.3M Q3 '23: -17.4M Q4 '23: -13.1M Q1 '24: -31.7M Q2 '24: -23.8M Q3 '24: -27.8M Q4 '24: -13.7M Q1 '25: -42.1M Q2 '25: -40M Q3 '25: -42.4M Q4 '25: -38.3M Q1 '26: -45.4M Q2 '26: -33.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '21: 22.2M Q2 '21: 22.3M Q3 '21: 22.4M Q1 '22: 22.6M Q2 '22: 22.7M Q3 '22: 22.8M Q1 '23: 23.3M Q2 '23: 23.5M Q3 '23: 32.3M Q4 '23: 36.2M Q1 '24: 37.1M Q2 '24: 40.5M Q3 '24: 46.8M Q4 '24: 47M Q1 '25: 47.4M Q2 '25: 47.7M Q3 '25: 48.1M Q1 '26: 50.2M Q2 '26: 50.4M Q1 '21 Q1 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '17: -3.20 Q1 '18: -0.58 Q2 '18: -1.02 Q3 '18: -2.28 Q4 '18: -3.00 Q1 '19: -2.77 Q2 '19: -2.71 Q3 '19: -2.49 Q4 '19: -2.89 Q1 '20: -5.79 Q2 '20: -6.15 Q3 '20: -6.40 Q4 '20: -5.92 Q1 '21: -5.30 Q2 '21: -5.03 Q3 '21: -5.07 Q4 '21: -4.96 Q1 '22: -5.04 Q2 '22: -5.05 Q3 '22: -4.83 Q4 '22: -4.81 Q1 '23: -4.86 Q2 '23: -4.71 Q3 '23: -4.26 Q4 '23: -3.73 Q1 '24: -3.30 Q2 '24: -3.09 Q3 '24: -2.92 Q4 '24: -3.00 Q1 '25: -3.05 Q2 '25: -3.28 Q3 '25: -3.46 Q4 '25: -3.19 Q1 '26: -2.74 Q2 '26: -1.97 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.